Vaccines & Disease · RSV

Respiratory Syncytial Virus (RSV) and RSV Vaccine Quick Facts

4 min read
01

RSV

  • Respiratory Syncytial Virus (RSV) is a common respiratory virus with symptoms similar to a mild cold, such as coughing, sneezing, wheezing, decreased appetite, fever, and malaise.1 The virus is contagious and is transmitted through coughing and sneezing, by coming into direct contact with the virus, and by touching surfaces that contain the virus and then touching your face.2
  • Young infants, children, older adults, and individuals with immune disorders and underlying chronic health diseases are more at risk of developing RSV infection and suffering from complications of the illness.3 By two years of age, most infants and children will have had RSV;4 however, it is possible to have more than one infection during an individual’s lifetime.5
  • Most individuals who develop an RSV infection will recover fully within one to two weeks without treatment. There are no specific treatments for RSV infection and symptoms can be treated with over-the-counter pain and fever medication, rest, and adequate hydration.6 Two monoclonal antibodies, Beyfortus (nirsevimab-alip)7 and Synagis (palivizumab)8, have been approved for use by the FDA for the prevention of RSV illness in infants and young children up to two years of age. These drugs, however, are not approved for the treatment of RSV infection.910
  • Individuals, especially young infants with small airways, may develop complications such as inflammation of the small airways in the lungs (bronchiolitis) or lung infection (pneumonia). Hospitalization may be required for individuals who have breathing problems, or who become dehydrated. Most people who require hospitalization will be discharged within a few days.11 Infants born prematurely, babies younger than six months of age, and young children with congenital heart and lung disorders, neuromuscular disorders, and those who are immunocompromised are at high risk of developing RSV infection and suffering complications.12 It is estimated that between four and five million children become infected with RSV in the U.S. each year, with an estimated 58,000 to 80,000 resulting in hospitalization.13
  • Adults with chronic health diseases, older adults, and those with immune disorders are also at risk of developing RSV illness and suffering complications from infection.14 The CDC estimates that between 60,000 and 120,000 older adults develop RSV infections that require hospitalization, with 6,000 to 10,000 of those contributing to death.15
02

RSV Vaccine

  • There are three RSV vaccines licensed for use in the US: ABRYSVO,16 a bivalent unadjuvanted prefusion F subunit vaccine manufactured by Pfizer; MRESVIA,17 an mRNA vaccine manufactured by Moderna; and AREXVY,18 a recombinant stabilized prefusion trimeric F (preF3) protein subunit vaccine, containing the AS01e adjuvant. ABRYSVO is licensed for use in adults 60 years of age and older and in pregnant women, for the prevention of RSV illness in their infants.19 AREXVY is licensed for use in adults 50 years of age and older,20 and MRESVIA is licensed for use in adults 60 years of age and older.21 The CDC’s use recommendation is for individuals 60 through 74 years of age considered at high risk for RSV illness and all persons 75 years of age and older to receive a single dose of the vaccine.22 RSV vaccines are also recommended for pregnant women, between 32 and 36 weeks’ gestation during the season when RSV is actively circulating.23
  • Higher rates of Guillain-Barré Syndrome (GBS),2425 a serious neurological disorder,26 and atrial fibrillation, a serious heart disorder, that may lead to complications such as stroke, heart attack, or heart failure,2728 were reported in vaccine recipients during clinical trials of both ABRYSVO and AREXVY vaccine. Clinical trial data also showed that when AREXVY was given at the same time as the quadrivalent influenza vaccine there was a significantly increased risk of Acute Disseminated Encephalomyelitis (ADEM), a serious and potentially fatal swelling of the brain and spinal cord.29
  • ABRYSVO clinical trial data for vaccinated pregnant women reported higher rates of preterm deliveries, pre-eclampsia, swelling of the hands and feet, protein in the urine, and gestational hypertension than those who received the placebo.30
  • According to data released January 2, 2026 by the CDC, 9,556 adverse reactions, including 93 deaths and 741 hospitalizations, have been reported to the Vaccine Adverse Event Reporting System (VAERS). Nearly 62 percent of adverse events occurred in persons 60 years of age and older.
03

Product Inserts & Resources

Food & Drug Administration (FDA): RSV Vaccines

  • AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) Package Insert and Licensing Information
  • ABRYSVO (Respiratory Syncytial Virus Vaccine) Package Insert and Licensing Information
  • MRESVIA (Respiratory Syncytial Virus Vaccine) Package Insert and Licensing Information

Food & Drug Administration (FDA): Monoclonal Antibodies

Centers for Disease Control (CDC)

04

Vaccine Reactions

Reporting a Vaccine Reaction

Since 1982, the NVIC has operated a Vaccine Reaction Registry, which has served as a watchdog on VAERS. Reporting vaccine reactions to VAERS is required by federal law under the National Childhood Vaccine Injury Act of 1986. If your doctor will not report a reaction, you have the right to report a suspected vaccine reaction to VAERS.

Vaccine Reaction Symptoms & Ingredients

NVIC’s Ask 8, If You Vaccinate webpage contains vaccine reaction symptoms.

Bottom Line
Vaccination is not a one-size-fits-all medical intervention. Before you take a risk, find out what it is.

Search for Vaccine Reactions

NVIC hosts MedAlerts, a powerful VAERS database search engine. MedAlerts examines symptoms, reactions, vaccines, dates, places, and more.

IMPORTANT NOTE: NVIC encourages you to become fully informed about Respiratory Syncytial Virus (RSV) and the RSV vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.

References
  1. 1US Centers for Disease Control and Prevention. Symptoms of RSV. June 5, 2024.
  2. 2US Centers for Disease Control and Prevention. How RSV Spreads. May 30, 2024.
  3. 3Jha A, Jarvis H, Fraser C, et al. Respiratory Syncytial Virus. June 1, 2016.
  4. 4US Centers for Disease Control and Prevention. Symptoms of RSV. June 5, 2024.
  5. 5US Centers for Disease Control and Prevention. How RSV spreads. Apr. 26, 2023.
  6. 6US Centers for Disease Control and Prevention. Symptoms of RSV. Sept. 6, 2023.
  7. 7US Food and Drug Administration. BEYFORTUS (nirsevimab-alip) – Package Insert. July 2023.
  8. 8US Food and Drug Administration. SYNAGIS® (palivizumab) – Package Insert. Mar. 2014.
  9. 9US Food and Drug Administration. BEYFORTUS (nirsevimab-alip) – Package Insert. July 2023.
  10. 10US Food and Drug Administration. SYNAGIS® (palivizumab) – Package Insert. Mar. 2014.
  11. 11US Centers for Disease Control and Prevention. RSV in Infants and Young Children. June 5, 2024.
  12. 12US Centers for Disease Control and Prevention. RSV in Infants and Young Children. June 5, 2024.
  13. 13US Centers for Disease Control and Prevention. RSV in Infants and Young Children. June 5, 2024.
  14. 14Jha A, Jarvis H, Fraser C, et al. Respiratory Syncytial Virus. June 1, 2016.
  15. 15US Centers for Disease Control and Prevention. RSV in Older Adults and Adults with Chronic Medical Conditions. June 5, 2024.
  16. 16Pfizer Inc. Package Insert – ABRYSVO. U.S. Food and Drug Administration. July 30, 2024.
  17. 17ModernaTX. Package Insert – MRESVIA. U.S. Food and Drug Administration. June 27, 2024.
  18. 18GlaxoSmithKline Biologicals SA. Package Insert – AREXVY. U.S. Food and Drug Administration. Aug. 22, 2024.
  19. 19Pfizer Inc. Package Insert – ABRYSVO. U.S. Food and Drug Administration. Mar. 18, 2024.
  20. 20GlaxoSmithKline Biologicals SA. Package Insert – AREXVY. U.S. Food and Drug Administration. Aug. 22, 2024.
  21. 21ModernaTX. Package Insert – MRESVIA. U.S. Food and Drug Administration. Aug. 22, 2024.
  22. 22US Centers for Disease Control and Prevention. CDC Updates RSV Vaccination Recommendation for Adults. June 26, 2024.
  23. 23US Centers for Disease Control and Prevention. CDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth. Sept. 22, 2023.
  24. 24US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee February 28–March 1, 2023 Meeting Briefing Document – FDA: Applicant – GSK. March 1, 2023.
  25. 25US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee February 28–March 1, 2023 Meeting Presentation – FDA Review of Efficacy and Safety of ABRYSVO BLA. March 1, 2023.
  26. 26National Library of Medicine Medline Plus. Guillain-Barre Syndrome. Feb. 1, 2016.
  27. 27US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee February 28–March 1, 2023 Meeting Briefing Document – FDA: Applicant – GSK. March 1, 2023.
  28. 28US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee February 28–March 1, 2023 Meeting Presentation – FDA Review of Efficacy and Safety of ABRYSVO BLA. March 1, 2023.
  29. 29NIH National Institute of Neurological Disorders and Stroke. Acute Disseminated Encephalomyelitis. Jan. 31, 2023.
  30. 30Pfizer. Bivalent RSV Prefusion F Vaccine for Maternal Immunization to Protect Infants. Presentation to the Vaccines and Related Biological Products Advisory Committee Meeting. May 18, 2023.
Select disease / vaccine